Answers are grounded in this paper and cite their sources.
Since loss of function mutations of PINK1 lead to early onset Parkinson's disease, there has been growing interest in the discovery of small molecules that amplify the kinase activity of PINK1. We herein report the design, synthesis, serum stability, and hydrolysis of four kinetin riboside ProTides. These ProTides, along with kinetin riboside, activated PINK1 in cells independent of mitochondrial depolarization. This highlights the potential of modified nucleosides and their phosphate prodrugs as treatments for neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Osgerby et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: